NF-κB inhibition: A double-edged sword in cancer?

Eli Pikarsky; Yinon Ben-Neriah

doi:10.1016/j.ejca.2006.01.011

NF-κB inhibition: A double-edged sword in cancer?

Eli Pikarsky^*
, Yinon Ben-Neriah

^*Corresponding author for this work

Department of Immunology and Cancer Research

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Abstract

Several recent studies of mouse models of cancer have provided direct genetic evidence for the critical role of NF-κB in carcinogenesis. While it has long been known that NF-κB is a key mediator of chemotherapy resistance, it is now clear that the transcription factor also has a major role in tumour development, particularly at its earlier phases. However, the role of NF-κB in tumourigenesis is more complex than anticipated, as in some models NF-κB inhibition blocks, whereas in others it facilitates, tumour development. In this paper we review current knowledge and suggest a general hypothesis that attempts to resolve this apparent paradox. Further cancer model studies should help to clarify this issue, complementing the intensive drug development effort of the pharmaceutical industry around NF-κB.

Original language	English
Pages (from-to)	779-784
Number of pages	6
Journal	European Journal of Cancer
Volume	42
Issue number	6
DOIs	https://doi.org/10.1016/j.ejca.2006.01.011
State	Published - Apr 2006

Bibliographical note

Funding Information:
Work in the laboratories of E.P. and Y.B.N. is supported by grants from Prostate Cancer Foundation Israel-Center of Excellence, the Israel Cancer Research Foundation, the Israel Science Foundation and the Association for international Cancer Research. We thank Drs. Rinnat Porat and Ilan Stein for critical discussions.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Animal models
Cancer
Carcinogens
Hepatocellular carcinoma
IKK
Inflammation
IκB
NF-κB
Squamous cell carcinoma
TNF

Access to Document

10.1016/j.ejca.2006.01.011

Cite this

@article{aae557edf48a4873a82b868438798f77,

title = "NF-κB inhibition: A double-edged sword in cancer?",

abstract = "Several recent studies of mouse models of cancer have provided direct genetic evidence for the critical role of NF-κB in carcinogenesis. While it has long been known that NF-κB is a key mediator of chemotherapy resistance, it is now clear that the transcription factor also has a major role in tumour development, particularly at its earlier phases. However, the role of NF-κB in tumourigenesis is more complex than anticipated, as in some models NF-κB inhibition blocks, whereas in others it facilitates, tumour development. In this paper we review current knowledge and suggest a general hypothesis that attempts to resolve this apparent paradox. Further cancer model studies should help to clarify this issue, complementing the intensive drug development effort of the pharmaceutical industry around NF-κB.",

keywords = "Animal models, Cancer, Carcinogens, Hepatocellular carcinoma, IKK, Inflammation, IκB, NF-κB, Squamous cell carcinoma, TNF",

author = "Eli Pikarsky and Yinon Ben-Neriah",

note = "Funding Information: Work in the laboratories of E.P. and Y.B.N. is supported by grants from Prostate Cancer Foundation Israel-Center of Excellence, the Israel Cancer Research Foundation, the Israel Science Foundation and the Association for international Cancer Research. We thank Drs. Rinnat Porat and Ilan Stein for critical discussions.",

year = "2006",

month = apr,

doi = "10.1016/j.ejca.2006.01.011",

language = "אנגלית",

volume = "42",

pages = "779--784",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - NF-κB inhibition

T2 - A double-edged sword in cancer?

AU - Pikarsky, Eli

AU - Ben-Neriah, Yinon

N1 - Funding Information: Work in the laboratories of E.P. and Y.B.N. is supported by grants from Prostate Cancer Foundation Israel-Center of Excellence, the Israel Cancer Research Foundation, the Israel Science Foundation and the Association for international Cancer Research. We thank Drs. Rinnat Porat and Ilan Stein for critical discussions.

PY - 2006/4

Y1 - 2006/4

N2 - Several recent studies of mouse models of cancer have provided direct genetic evidence for the critical role of NF-κB in carcinogenesis. While it has long been known that NF-κB is a key mediator of chemotherapy resistance, it is now clear that the transcription factor also has a major role in tumour development, particularly at its earlier phases. However, the role of NF-κB in tumourigenesis is more complex than anticipated, as in some models NF-κB inhibition blocks, whereas in others it facilitates, tumour development. In this paper we review current knowledge and suggest a general hypothesis that attempts to resolve this apparent paradox. Further cancer model studies should help to clarify this issue, complementing the intensive drug development effort of the pharmaceutical industry around NF-κB.

AB - Several recent studies of mouse models of cancer have provided direct genetic evidence for the critical role of NF-κB in carcinogenesis. While it has long been known that NF-κB is a key mediator of chemotherapy resistance, it is now clear that the transcription factor also has a major role in tumour development, particularly at its earlier phases. However, the role of NF-κB in tumourigenesis is more complex than anticipated, as in some models NF-κB inhibition blocks, whereas in others it facilitates, tumour development. In this paper we review current knowledge and suggest a general hypothesis that attempts to resolve this apparent paradox. Further cancer model studies should help to clarify this issue, complementing the intensive drug development effort of the pharmaceutical industry around NF-κB.

KW - Animal models

KW - Cancer

KW - Carcinogens

KW - Hepatocellular carcinoma

KW - IKK

KW - Inflammation

KW - IκB

KW - NF-κB

KW - Squamous cell carcinoma

KW - TNF

UR - https://www.scopus.com/pages/publications/33646488626

U2 - 10.1016/j.ejca.2006.01.011

DO - 10.1016/j.ejca.2006.01.011

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16530406

AN - SCOPUS:33646488626

SN - 0959-8049

VL - 42

SP - 779

EP - 784

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 6

ER -

NF-κB inhibition: A double-edged sword in cancer?

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this